HOME >> BIOLOGY >> NEWS
Other highlights in the September 21 JNCI

Study Reports Elevated Risk of Second Cancers for Testicular Cancer Survivors

Men who survive testicular cancer have an increased risk of developing a second cancer for at least 35 years after diagnosis, according to the largest study to date of testicular cancer survivors.

Testicular cancer largely affects young men, and the 10-year survival rate of the disease is as high as 95%, so most men survive testicular cancer. However, these men have an increased risk of developing second cancers, mostly because of the late side effects of treatment. These cancers are a leading cause of death for testicular cancer patients.

To determine the risks of second cancers among long-term survivors of testicular cancer, Lois B. Travis, M.D., of the National Cancer Institute, and colleagues examined data from 40,576 1-year survivors of testicular cancer from population-based tumor registries in Europe and North America. A total of 2,285 second solid cancers were reported among these men anywhere from 1 year to more than 35 years after their testicular cancer diagnosis.

Ten-year survivors who had been diagnosed with testicular cancer at age 35 had a risk of developing a second cancer that was nearly twice that of the general population, and this risk remained elevated for 35 years. Risks were higher for patients diagnosed with testicular cancer at younger ages and lower for patients diagnosed at older ages. Cancers of the bladder, colon, lung, pancreas, and stomach accounted for 60% of the total excess risk. The authors conclude that testicular cancer survivors are at increased risk of solid tumors for at least 35 years after treatment and that young patients may face high levels of risk as they get older.

Contact: National Cancer Institute Press Office, 301-496-6641, NCIPressOfficers@mail.nih.gov

Hormone Replacement Therapy Associated With Increases in Mammographic Breast Den
'"/>

Contact: Sarah L. Zielinski
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Sep-2005


Page: 1 2 3 4 5

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights in JNCI, June 12
6. Other highlights from the June 6 JNCI
7. Other highlights in the May 16 JNCI
8. Other highlights from the April 18 Journal of the National Cancer Institute
9. Other highlights from the March 21 JNCI
10. Other highlights in the March 7 JNCI
11. Other highlights in the Feb. 21 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
Breaking Biology Technology:
Cached News: